About Laverock Therapeutics
Laverock Therapeutics is a company based in Stevenage (United Kingdom) founded in 2021.. Laverock Therapeutics has raised $66.78 million across 3 funding rounds from investors including Lilly, Mercia and Maven Capital Partners. The company has 6 employees as of December 31, 2022. Laverock Therapeutics operates in a competitive market with competitors including Senti Biosciences, Caribou Biosciences, Sana Biotechnology, Immunocore and Semma Therapeutics, among others.
- Headquarter Stevenage, United Kingdom
- Employees 6 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Laverock Therapeutics Limited
- Date of Incorporation 13 Jul, 2021
- Jurisdiction ROMSEY, ENGLAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$66.78 M (USD)
in 3 rounds
-
Latest Funding Round
$27.5 M (USD), Seed
Jun 30, 2025
-
Investors
Lilly
& 8 more
-
Employee Count
6
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Laverock Therapeutics
Laverock Therapeutics has successfully raised a total of $66.78M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $27.5 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Seed — $27.5M
-
First Round
First Round
(08 Aug 2022)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2025 | Amount | Seed - Laverock Therapeutics | Valuation | Calculus Capital | |
| Sep, 2023 | Amount | Seed - Laverock Therapeutics | Valuation | Calculus Capital | |
| Aug, 2022 | Amount | Seed - Laverock Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Laverock Therapeutics
Laverock Therapeutics has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Mercia and Maven Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
UK venture capital investments are managed by Calculus Capital.
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for private equity investments.
|
Founded Year | Domain | Location | |
|
Early-stage innovations are funded by UKI2S across key sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Laverock Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Laverock Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Laverock Therapeutics Comparisons
Competitors of Laverock Therapeutics
Laverock Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Caribou Biosciences, Sana Biotechnology, Immunocore and Semma Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer
|
|
| domain | founded_year | HQ Location |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| domain | founded_year | HQ Location |
Therapeutics for diabetes and obesity treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Laverock Therapeutics
Frequently Asked Questions about Laverock Therapeutics
When was Laverock Therapeutics founded?
Laverock Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is Laverock Therapeutics located?
Laverock Therapeutics is headquartered in Stevenage, United Kingdom. It is registered at Stevenage, Hertfordshire, United Kingdom.
Who is the current CEO of Laverock Therapeutics?
David Venables is the current CEO of Laverock Therapeutics.
Is Laverock Therapeutics a funded company?
Laverock Therapeutics is a funded company, having raised a total of $66.78M across 3 funding rounds to date. The company's 1st funding round was a Seed of $22.89M, raised on Aug 08, 2022.
How many employees does Laverock Therapeutics have?
As of Dec 31, 2022, the latest employee count at Laverock Therapeutics is 6.
What does Laverock Therapeutics do?
Laverock Therapeutics was founded in 2021 in Stevenage, United Kingdom, within the biotechnology sector. Programmable cell therapies are engineered through gene editing induced gene silencing (GEiGS) technology and an associated computational platform. Induced pluripotent stem cell (iPSC)-derived therapies are created for therapeutic applications, with operations focused on advancing cell-based treatments in the region.
Who are the top competitors of Laverock Therapeutics?
Laverock Therapeutics's top competitors include Immunocore, Achilles Therapeutics and Autolus.
Who are Laverock Therapeutics's investors?
Laverock Therapeutics has 9 investors. Key investors include Lilly, Mercia, Maven Capital Partners, Calculus Capital, and UKI2S.